Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy

References

• YinHKauffmanKJAndersonDGDelivery technologies for genome editingNat Rev Drug Discov201716638739928337020
   PubMed Web of Science ®Google Scholar
• BoycottKMVanstoneMRBulmanDEMackenzieAERare-disease genetics in the era of next-generation sequencing: discovery to translationNat Rev Genet2013141068169123999272
   PubMed Web of Science ®Google Scholar
• America PRaMoMedicines In DevelopmentRare Diseases: A Report On Orphan Drugs In The Pipeline Presented By America’s Biopharmaceutical Research Companies2013 Available from: PhRMA.orghttp://phrma-docsphrmaorg/sites/default/files/pdf/Rare_Diseases_2013.pdf
   Google Scholar
• CongLRanFACoxDMultiplex genome engineering using CRISPR/Cas systemsScience2013339612181982323287718
   PubMed Web of Science ®Google Scholar
• DoudnaJACharpentierEGenome editing. The new frontier of genome engineering with CRISPR-Cas9Science20143466213125809625430774
   PubMed Web of Science ®Google Scholar
• MaliPYangLEsveltKMRNA-guided human genome engineering via Cas9Science2013339612182382623287722
   PubMed Web of Science ®Google Scholar
• MaliPEsveltKMChurchGMCas9 as a versatile tool for engineering biologyNat Methods2013101095796324076990
   PubMed Web of Science ®Google Scholar
• SanderJDJoungJKCRISPR-Cas systems for editing, regulating and targeting genomesNat Biotechnol201432434735524584096
   PubMed Web of Science ®Google Scholar
• UrnovFDRebarEJHolmesMCZhangHSGregoryPDGenome editing with engineered zinc finger nucleasesNat Rev Genet201011963664620717154
   PubMed Web of Science ®Google Scholar
• ChenYWangZNiHXuYChenQJiangLCRISPR/Cas9-mediated base-editing system efficiently generates gain-of-function mutations in ArabidopsisSci China Life Sci201760552052328303459
   PubMed Web of Science ®Google Scholar
• JoungJKSanderJDTALENs: a widely applicable technology for targeted genome editingNat Rev Mol Cell Biol2013141495523169466
   PubMed Web of Science ®Google Scholar
• HeZYDengFWeiXWOvarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplexSci Rep201662376427026065
   PubMed Web of Science ®Google Scholar
• OsakabeYWatanabeTSuganoSSOptimization of CRISPR/Cas9 genome editing to modify abiotic stress responses in plantsSci Rep201662668527226176
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• GajTGersbachCABarbasCFZFN, TALEN, and CRISPR/Cas-based methods for genome engineeringTrends Biotechnol201331739740523664777
   PubMed Web of Science ®Google Scholar
• HilleFCharpentierECRISPR-Cas: biology, mechanisms and relevancePhilos Trans R Soc Lond B Biol Sci201637117072015049627672148
   PubMed Web of Science ®Google Scholar
• SavićNSchwankGAdvances in therapeutic CRISPR/Cas9 genome editingTransl Res2016168152126470680
   PubMed Web of Science ®Google Scholar
• CoxDBPlattRJZhangFTherapeutic genome editing: prospects and challengesNat Med201521212113125654603
   PubMed Web of Science ®Google Scholar
• HeZYMenKQinZYangYXuTWeiYQNon-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical fieldSci China Life Sci201760545846728527117
   PubMed Web of Science ®Google Scholar
• YinHSongCQDorkinJRTherapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivoNat Biotechnol201634332833326829318
   PubMed Web of Science ®Google Scholar
• LiLHeZYWeiXWGaoGPWeiYQChallenges in CRISPR/CAS9 Delivery: potential roles of nonviral vectorsHum Gene Ther201526745246226176432
   PubMed Web of Science ®Google Scholar
• BoussifOLezoualc’hFZantaMAA versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimineProc Natl Acad Sci U S A19959216729773017638184
   PubMed Web of Science ®Google Scholar
• KunathKvon HarpeAFischerDLow-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimineJ Control Release200389111312512695067
   PubMed Web of Science ®Google Scholar
• GuoGZhouLChenZAlkane-modified low-molecular-weight polyethylenimine with enhanced gene silencing for siRNA deliveryInt J Pharm20134501–2445223608201
   PubMedGoogle Scholar
• ThapaBPlianwongSRemant BahadurKCRutherfordBUludağHSmall hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective deliveryActa Biomater20163321322426802444
   PubMed Web of Science ®Google Scholar
• LiuSHuangWJinMJHigh gene delivery efficiency of alkylated low-molecular-weight polyethylenimine through gemini surfactant-like effectInt J Nanomedicine201493567358125114526
   PubMed Web of Science ®Google Scholar
• KratzFAlbumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticlesJ Control Release2008132317118318582981
   PubMed Web of Science ®Google Scholar
• StehleGSinnHWunderAPlasma protein (albumin) catabolism by the tumor itself – implications for tumor metabolism and the genesis of cachexiaCrit Rev Oncol Hematol1997262771009298326
   PubMed Web of Science ®Google Scholar
• ElsadekBKratzFImpact of albumin on drug delivery – new applications on the horizonJ Control Release2012157142821959118
   PubMed Web of Science ®Google Scholar
• MalhotraAMittalBRSiRNA gene therapy using albumin as a carrierPharmacogenet Genomics2014241258258725322287
   PubMed Web of Science ®Google Scholar
• NicolìESygaMIBosettiMShastriVPEnhanced gene silencing through human serum albumin-mediated delivery of polyethylenimine-siRNA polyplexesPLoS One2015104e012258125856158
   PubMed Web of Science ®Google Scholar
• ThaoLeQByeonHJLeeCDoxorubicin-bound albumin nanoparticles containing a TRAIL protein for targeted treatment of colon cancerPharm Res201633361562626526555
   PubMed Web of Science ®Google Scholar
• MinSYByeonHJLeeCFacile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancerInt J Pharm2015494150651526315118
   PubMedGoogle Scholar
• WangXTengFKongLYuJPD-L1 expression in human cancers and its association with clinical outcomesOnco Targets Ther201695023503927574444
   PubMed Web of Science ®Google Scholar
• HaeusslerMSchönigKEckertHEvaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPORGenome Biol201617114827380939
   PubMed Web of Science ®Google Scholar
• KleinovinkJWMarijtKASchoonderwoerdMJAvan HallTOssendorpFFransenMFPD-L1 expression on malignant cells is no prerequisite for checkpoint therapyOncoimmunology201764e129429928507803
   PubMed Web of Science ®Google Scholar
• WuYGuWTangJXuZPZpXDevising new lipid-coated calcium phosphate/carbonate hybrid nanoparticles for controlled release in endosomes for efficient gene deliveryJ Mater Chem B201753471947203
   PubMed Web of Science ®Google Scholar
• ChoiJKHoJCurrySQinDBittmanRHamiltonJAInteractions of very long-chain saturated fatty acids with serum albuminJ Lipid Res20024371000101012091483
   PubMed Web of Science ®Google Scholar
• NeamnarkASuwantongOBahadurRKHsuCYSupapholPUludağHAliphatic lipid substitution on 2 kDa polyethylenimine improves plasmid delivery and transgene expressionMol Pharm2009661798181519719326
   PubMedGoogle Scholar
• BahadurKCLandryBAliabadiHMLavasanifarAUludağHLipid substitution on low molecular weight (0.6–2.0 kDa) polyethylenimine leads to a higher zeta potential of plasmid DNA and enhances transgene expressionActa Biomater2011752209221721256988
   PubMed Web of Science ®Google Scholar
• LiJLiangHLiuJWangZPoly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapyInt J Pharm20185461–221522529787895
   PubMed Web of Science ®Google Scholar
• LiuJLiJLiuNIn vitro studies of phospholipid-modified PAMAM-siMDR1 complexes for the reversal of multidrug resistance in human breast cancer cellsInt J Pharm20175301–229129928619457
   PubMed Web of Science ®Google Scholar